Type 2 Diabetes (T2D) Treatments

Find Type 2 Diabetes (T2D) Treatments

Generic Name

MetFORMIN

Brand Names

Actoplus, Alogliptin, Dapagliflozin, Glipizide, Glumetza, Glyburide, Glyburide-MetFORMIN, Invokamet, Janumet, Jentadueto, Kazano, Linagliptin, Pioglitazole, Pioglitazone, Riomet, Saxagliptin, Segluromet, Sitagliptin, Synjardy, Trijardy, Xigduo, Zituvimet

FDA approval date: January 24, 2002

Classification: Sodium-Glucose Cotransporter 2 Inhibitor

Form: Tablet, Solution

What is Actoplus (MetFORMIN)?

ACTOPLUS MET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ACTOPLUS MET is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis. ACTOPLUS MET is a combination of pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, and metformin hydrochloride , a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : Not recommended for treatment of type 1 diabetes or diabetic ketoacidosis.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Who is this study for: Patients with Multiple Sclerosis

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug

Study Drugs: Pioglitazone, Clemastine Fumarate, Hydroxychloroquine, Dantrolene

Study Phase: Phase 1/Phase 2

Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to.

Targeting Myeloid-Derived Suppressor Cells in Patients With Recurrent/Progressive Grade 4 Glioma: Phase 1 Trial of Sitagliptin

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Biological, Drug

Study Phase: Phase 1

Summary: Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Artery Bypass Grafting: a Prospective Single-Center Study

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Summary: This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin)...

View All Clinical Trials